Immunovant, Inc. (IMVT)

Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	77.24	57.28	48.02	54.23	39.51
Research & Development	360.92	212.93	160.26	101.81	68.6
Operating Expenses	438.15	270.21	208.28	156.03	108.12
Operating Income	-438.15	-270.21	-208.28	-156.03	-108.12
Interest & Investment Income	24.73	24.95	7.58	-	-
Other Non Operating Income (Expenses)	0.47	-1.01	-0.25	-0.78	0.33
EBT Excluding Unusual Items	-412.95	-246.27	-200.95	-156.81	-107.79
Pretax Income	-412.95	-258.77	-210.95	-156.81	-107.79
Income Tax Expense	0.89	0.57	0.01	-0.08	-0.36
Net Income	-413.84	-259.34	-210.96	-156.73	-107.43
Net Income to Common	-413.84	-259.34	-210.96	-156.73	-107.43
Shares Outstanding (Basic)	152	138	123	110	88
Shares Outstanding (Diluted)	152	138	123	110	88
Shares Change (YoY)	9.76%	12.21%	12.21%	24.98%	103.14%
EPS (Basic)	-2.73	-1.88	-1.71	-1.43	-1.22
EPS (Diluted)	-2.73	-1.88	-1.71	-1.43	-1.22
Free Cash Flow	-376.63	-214.59	-188.39	-106.37	-83.54
Free Cash Flow Per Share	-2.48	-1.55	-1.53	-0.97	-0.95
EBITDA	-437.78	-269.98	-208.08	-155.91	-108.05
D&A For EBITDA	0.38	0.23	0.19	0.13	0.07
EBIT	-438.15	-270.21	-208.28	-156.03	-108.12

Updated May 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q